New treatment for African sleeping sickness comes closer
[2013-11-05] Researchers at Umeå University have identified drugs targeting infections of the parasite Trypanosoma brucei and are thereby well on the way to find a cure against African sleeping sickness. This is the kernel of a thesis, which will be publicly defended on 8 November 2013.
African sleeping sickness (Human African trypanosomiasis) is caused by a parasite called Trypanosoma brucei. As the name of the disease indicates, it is associated with sleep disturbances but there are many other neurological complications as well. Unless the patient is treated, the illness develops in stages and leads eventually to unconsciousness and death. At present, there is no vaccine available and the medicines that exist are either very toxic or do not work effectively against all variants of the disease.
All cells have the potential to renew themselves infinitely through cell division. During cell division, the cell replicates its DNA, which constitutes the individual’s genetic material, and then allows the DNA copy to pass on to the daughter cell. During this process, there is a need for a continuous supply of four different building blocks for DNA, i.e. dATP, dCTP, dTTP and dGTP. In human cells, these DNA building blocks can either be produced by the cells themselves, or absorbed in the form of so-called precursor molecules (deoxynucleosides) that are present in the blood and other body fluids.
It has already been observed that the parasite’s production of RNA building blocks, which resemble DNA building blocks, could be a target for drug discovery whereas the parasite’s production of DNA building blocks has not been studied to the same extent. Munender Vodnala from the Department of Medical Biochemistry and Biophysics has therefore focused his study on the cellular machinery involved in the production of DNA building blocks from precursor molecules. This is considered to be a promising target for drug development against the parasite.
The production of DNA building blocks from precursor molecules is made in three stages, so-called phosphorylations. Munender Vodnala has demonstrated that the enzyme adenosine kinase, which is involved in the first production stage, can be used by the parasite to produce dATP from the precursor molecule deoxyadenosine. When the parasite Trypanosoma brucei is cultivated in the presence of large amounts of deoxyadenosine, it produces high levels of dATP compared with mammalian cells. At these levels, dATP becomes toxic to the parasites and they die within just a few hours. Furthermore, Munender Vodnala has managed to identify two modified versions of deoxyadenosine, so-called analogues of deoxyadenosine. These resemble - but are significantly more effective than - deoxyadenosine itself in killing off the parasites.
“When we used deoxyadenosine analoues to treat mice that were infected with Trypanosoma brucei, we were able to cure the infections very successfully. These results indicate that we can now move on to develop an effective treatment for African sleeping sickness,” explains Munender Vodnala.
Munender Vodnala comes from Hyderabad in India. He is a biochemist and molecular biologist as well as being a doctoral candidate at the Department of Medical Biochemistry and Biophysics, Umeå University, Sweden. You can contact him at:
Tel: +46 73-951 29 71
On 8 November 2013, Munender Vodnala, Department of Medical Biochemistry and Biophysics, defends his thesis with the title: Läkemedelsutveckling mot nukleotidmetabolismen hos den mammala patogenen Trypanosoma brucei. (English title: Targeting the nucleotide metabolism of the mammalian pathogen Trypanosoma brucei).
Opponent: Professor Arne Holmgren, Department of Medical Biochemistry and Biophysics, Division of Biochemistry, Karolinska Institutet.
Main Supervisor: Anders Hofer.
The thesis is published digitally at
Editor: Mattias Grundström Mitz
Link to news:
Leading experts in infection research celebrated Knut and Alice Wallenberg Foundation's 100 year anniversary